Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
8(80%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
20%
Ph phase_2
6
60%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
6(66.7%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

10

all time

Status Distribution
Active(9)
Completed(1)

Detailed Status

Recruiting8
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
8
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 26 (66.7%)
Phase 32 (22.2%)

Trials by Status

completed110%
not_yet_recruiting110%
recruiting880%

Recent Activity

8 active trials
Showing 5 of 10
recruitingphase_3

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110
recruitingphase_1

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

NCT07407283
completed

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

NCT07428642
recruitingphase_2

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

NCT06348264
recruitingphase_2

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

NCT06387056
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07611110Phase 3

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Recruiting
NCT07407283Phase 1

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Recruiting
NCT07428642

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Completed
NCT06348264Phase 2

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Recruiting
NCT06387056Phase 2

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Recruiting
NCT06305832Phase 2

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting
NCT06134271Phase 2

Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

Not Yet Recruiting
NCT05983783Phase 3

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Recruiting
NCT05753566Phase 2

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting
NCT05406999Phase 2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Recruiting

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10